文献速递头颈神经MRUS

鼻咽癌颈部淋巴结转移:Node-RADS 与大小标准病理对照验证

Head-to-head pathologic validation of Node-RADS vs size-based criteria for cervical lymph node metastasis in nasopharyngeal carcinoma.
PubMed 文献 · Eur Radiol · 2026-06-10

回顾性纳入 273 例鼻咽癌患者的 335 枚经超声引导细针穿刺细胞学验证的颈部淋巴结,两名放射科医生独立按 Node-RADS 评分。Node-RADS≥4 诊断转移的敏感度 96.0%、特异度 98.9%,AUC 0.97,显著高于传统大小标准 AUC 0.82。在 227 枚大小阴性淋巴结中,Node-RADS 仍正确识别 49 枚转移淋巴结中的 43 枚。

要点

  • Node-RADS≥4 诊断颈部淋巴结转移具有高敏感度与高特异度,优于传统大小标准
  • 对大小未达标准但 Node-RADS 高的淋巴结应警惕转移,避免漏诊
  • Node-RADS 可用于鼻咽癌 N 分期和放疗靶区勾画参考

核心结论

  • Node-RADS 在鼻咽癌颈部淋巴结转移诊断中显著优于传统大小标准,尤以大小阴性淋巴结获益明显
  • Node-RADS≥4 时诊断转移的敏感度 96.0%、特异度 98.9%,AUC 0.97(95%CI 0.96-0.99)
  • 在 227 枚大小阴性淋巴结中 Node-RADS 敏感度 87.8%、特异度 99.4%,AUC 0.94(95%CI 0.89-0.98),正确识别 49 枚转移淋巴结中 43 枚

研究设计与样本

  • 回顾性研究,纳入 2014 年 3 月至 2023 年 4 月病理确诊鼻咽癌并接受超声引导细针穿刺细胞学的患者
  • 共 273 例患者(男性 202 例;中位年龄 51.0 岁,IQR 37-65)335 枚颈部淋巴结,其中 150 枚(44.8%)细胞学为恶性
  • 穿刺前 7 天内均完成治疗前头颈部 MRI,两名设盲放射科医生按标准化流程独立对每枚穿刺淋巴结进行 Node-RADS 1-5 评分
  • 以超声引导细针穿刺细胞学结果为参考标准,用 ROC 分析比较 Node-RADS 与常规大小标准诊断效能

关键影像表现/征象

  • 按标准化 Node-RADS 流程对头颈部 MRI 上每个穿刺淋巴结评分 1-5 分
  • Node-RADS 与传统大小标准均基于鼻咽癌治疗前头颈部 MRI 图像进行淋巴结评估

诊断标准与关键数值

  • 以 Node-RADS≥4 为阈值时诊断颈部淋巴结转移的敏感度 96.0%,特异度 98.9%,AUC 0.97(95%CI 0.96-0.99)
  • 传统大小标准诊断颈部淋巴结转移的 AUC 0.82(95%CI 0.79-0.86),Node-RADS AUC 显著高于大小标准(p < 0.05)
  • 在 227 枚大小阴性淋巴结中,Node-RADS 诊断转移敏感度 87.8%,特异度 99.4%,AUC 0.94(95%CI 0.89-0.98)
  • 在大小标准漏诊的 49 枚转移淋巴结中,Node-RADS 正确识别 43 枚

临床应用与阅片要点

  • 对鼻咽癌 MRI 报告的颈部淋巴结可采用 Node-RADS 评分,Node-RADS≥4 应提示转移
  • 对大小未达传统标准的颈部淋巴结仍需按 Node-RADS 评估,避免因大小阈值漏诊转移
  • Node-RADS 高敏感且高特异,可用于支持更准确的 N 分期和放疗靶区勾画

局限性

  • 研究为回顾性设计,来自原文所述的单中心患者队列
  • 参考标准为超声引导细针穿刺细胞学结果,仅涵盖穿刺淋巴结而非所有颈部淋巴结

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Accurate diagnosis of cervical lymph node (CLN) metastasis is essential for staging nasopharyngeal carcinoma (NPC). Conventional size-based MRI criteria exhibit high specificity but low sensitivity, leading to underdiagnosis. This study pathologically validated the Node Reporting and Data System (Node-RADS) vs size criteria for diagnosing CLN metastasis in NPC.

MATERIALS AND METHODS: Patients with histologically confirmed NPC who underwent ultrasound-guided fine-needle aspiration cytology (FNAC) of CLNs between March 2014 and April 2023 were included. All patients had a pretreatment head and neck MRI within 7 days before FNAC. Two blinded radiologists independently assigned Node-RADS scores (1-5) to each biopsied node according to the standardized workflow. Diagnostic performance was compared against conventional size-based criteria using receiver operating characteristic (ROC) analysis.

RESULTS: A total of 273 patients (202 men; median age, 51.0 years [IQR: 37-65]) with 335 CLNs were included, of which 150 (44.8%) were malignant on FNAC. Using a cutoff of Node-RADS ≥ 4, sensitivity and specificity were 96.0% and 98.9%, respectively, with an AUC of 0.97 (95% CI: 0.96-0.99), significantly higher than that of size-based criteria (AUC, 0.82; 95% CI: 0.79-0.86, p < 0.05). Among 227 size-negative nodes, Node-RADS achieved a sensitivity of 87.8% and specificity of 99.4%, correctly identifying 43 of 49 metastatic nodes missed by size criteria (AUC, 0.94; 95% CI: 0.89-0.98).

CONCLUSION: The Node-RADS system significantly outperforms conventional size-based criteria for detecting CLN metastasis in NPC, particularly in size-negative nodes. By offering high sensitivity while maintaining excellent specificity, Node-RADS represents a robust imaging tool that could enhance nodal staging accuracy and precise treatment planning.

KEY POINTS: Question Can a standardized MRI-based nodal scoring system improve the detection of metastatic CLNs in NPC, particularly when nodes remain below conventional size thresholds? Findings In this pathologically validated cohort, Node-RADS outperformed conventional size criteria and correctly identified most metastatic CLNs missed by size-based assessment. Clinical relevance The Node-RADS improves MRI-based detection of metastatic CLNs in NPC while preserving high specificity, supporting more accurate nodal staging and more precise radiotherapy target delineation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Huang, Wu, Huang, et al. Head-to-head pathologic validation of Node-RADS vs size-based criteria for cervical lymph node metastasis in nasopharyngeal carcinoma. Eur Radiol. 2026. PMID: 42268307. doi:10.1007/s00330-026-12675-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。